Rendering

Component: (Network and Table)
Network
105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS
(http://www.acurapharm.com/taxonomy/role/StatementOfIncomeAlternative)
TableStatement [Table]
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0000786947 (http://www.sec.gov/CIK)
Legal Entity [Axis]Entity [Domain]
Statement [Line Items]Period [Axis]
2011-01-01 - 2011-12-31
2010-01-01 - 2010-12-31
2009-01-01 - 2009-12-31
Revenues
 
 
 
Program fee revenue
466,000  
1,088,000  
3,077,000  
Collaboration revenue
0  
2,223,000  
758,000  
Milestone revenue
20,000,000  
0  
0  
Total revenue
20,466,000  
 
3,311,000  
 
3,835,000  
 
Operating expenses
 
 
 
Research and development
4,037,000  
7,177,000  
5,673,000  
Marketing, general and administrative
5,895,000  
8,858,000  
11,662,000  
Total operating expenses
9,932,000  
 
16,035,000  
 
17,335,000  
 
Income (loss) from operations
10,534,000  
 
(12,724,000) 
 
(13,500,000) 
 
Other income (expense)
 
 
 
Interest income
32,000  
42,000  
147,000  
Other expense
(34,000) 
(14,000) 
(3,000) 
Total other income (expense)
(2,000) 
 
28,000  
 
144,000  
 
Income (loss) before income tax
10,532,000  
 
(12,696,000) 
 
(13,356,000) 
 
Income tax expense
147,000  
11,000  
2,479,000  
Net income (loss) applicable to common stockholders
10,385,000  
 
(12,707,000) 
 
(15,835,000) 
 
Earnings (loss) per share
 
 
 
Basic
.22  
(.27) 
(.35) 
Diluted
.22  
(.27) 
(.35) 
Weighted average shares
 
 
 
Basic
47,496,000  
47,029,000  
45,932,000  
Diluted
48,007,000  
47,029,000  
45,932,000